Claims
- 1. A compound having the structure:
- 2. A method for inhibiting the activity of an A3 adenosine receptor in a cell, which comprises contacting the cell with a compound of claim 1.
- 3. The method of claim 2, wherein the compound is an antagonist of the A3 adenosine receptor.
- 4. The method of claim 2, wherein the cell is human cell.
- 5. The method of claim 4, wherein the compound is an antagonist of A3 adenosine receptors.
- 6. A method of treating damage to the eye of a subject which comprises administering to the subject a composition comprising a therapeutically effective amount of the compound of claim 1.
- 7. The method of claim 6, wherein the damage comprises retinal or optic nerve head damage.
- 8. A therapy for glaucoma, comprising administering to a subject a therapeutically effective amount of the compound of claim 1.
- 9. A combination therapy for glaucoma, comprising the compound of claim 1, and one or more compounds selected from the group consisting of beta adrenoceptor antagonists, alpha-2 adrenoceptor agonists, carbonic anhydrase inhibitors, cholinergic agonists, prostaglandins and prostaglandin receptor agonists, angiotensin converting enzyme (ACE) inhibitors, AMPA receptor antagonists, 5-HT agonists, angiogenesis inhibitors, NMDA antagonists, renin inhibitors, cannabinoid receptor agonists, angiotensin receptor antagonists, hydrochlorothiazide (HCTZ), somatostatin agonists, glucocorticoid antagonists, mast cell degranulation inhibitors, alpha-adrenergic receptor blockers, alpha-2 adrenoceptor antagonists, thromboxane A2 mimetics, protein kinase inhibitors, prostaglandin F derivatives, prostaglandin-2 alpha antagonists, dopamine D1 and 5-HT2 agonists, nitric-oxide-releasing agents, 5-HT 2 antagonists, cyclooxygenase inhibitors, inosine, dopamine D2 receptor and alpha 2 adrenoceptor agonists, dopamine D1 receptor antagonist and D2 receptor agonists, vasopressin receptor antagonists, endothelin antagonists, 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and related analogs and prodrugs, thyroid hormone receptor ligands, muscarinic M1 agonists, sodium channel blockers, mixed-action ion channel blockers, beta adrenoceptor antagonist and PGF2 alpha agonist combinations, guanylate cyclase activators, nitrovasodilators, endothelin receptor modulators, ethacrynic acid, other phenoxyacetic acid analogs, actin disrupters, calcium channel blockers and neuroprotective agents.
- 10. A combination therapy for glaucoma, comprising the compound of claim 1, and one or more compounds selected from the group consisting of beta adrenoceptor antagonists, alpha-2 adrenoceptor agonists, carbonic anhydrase inhibitors, cholinergic agonists and prostaglandin receptor agonists.
- 11. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.
- 12. A packaged pharmaceutical composition for treating a disease associated with A3 adenosine receptor in a subject, comprising:
(a) a container holding a therapeutically effective amount of the compound of claim 1; and (b) instructions for using said compound for treating said disease in a subject.
- 13. A method of making a composition which comprises the compound of claim 1, the method comprising admixing the compound of claim 1 with a suitable carrier.
- 14. A pharmaceutically acceptable salt of the compound of claim 1.
- 15. The pharmaceutically acceptable salt of claim 14, wherein the pharmaceutically acceptable salt contains an anion selected from the group consisting of maleic, fumaric, tartaric, acetate, phosphate and mesylate.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Application No. 60/250,748, filed on Dec. 1, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60250748 |
Dec 2000 |
US |